Evidence map›Paper›PMID 34716979›Full record

Trial reportCancer science2022

Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.

Tadahiro Shoji, Takayuki Enomoto, Masakazu Abe, Aikou Okamoto, Takayuki Nagasawa, Tetsuro Oishi, Satoru Nagase, Masahiko Mori, Yuki Inokuchi, Shoji Kamiura and 3 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.The Cochrane database of systematic reviews · 2023
    Pooled it
  5. Trial
  6. α2,3-Sialyltransferase (ST3Gal1) regulates endometrioid-type epithelial ovarian cancer cell migration and invasion via VEGF-R2/JAK2/STAT3 signaling cascades.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 1 country.

Tadahiro ShojiDepartment of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan.ORCID https://orcid.org/0000-0002-9022-3333
Takayuki EnomotoDepartment of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata, Japan.
Masakazu AbeDepartment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Aikou OkamotoDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Takayuki NagasawaDepartment of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan.
Tetsuro OishiDepartment of Obstetrics and Gynecology, Tottori University School of Medicine, Tottori, Japan.
Satoru NagaseDepartment of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Masahiko MoriDepartment of Gynecology, Aichi Cancer Center Hospital, Aichi, Japan.
Yuki InokuchiDepartment of Biostatistics, Kitasato Academic Research Organization, Kitasato University, Tokyo, Japan.
Shoji KamiuraDepartment of Gynecologic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Shinichi KomiyamaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Toho University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0420-5700
Nobuhiro TakeshimaDepartment of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Toru SugiyamaDepartment of Obstetrics and Gynecology, St. Mary's Hospital, Fukuoka, Japan.
Iwate Medical University · JPAichi Cancer Center · JPJikei University School of Medicine · JPKitasato University · JPNiigata University · JPOsaka International Cancer Institute · JPShizuoka Cancer Center · JPSt Mary's Hospital · JPThe Cancer Institute Hospital · JPToho University · JPTottori University · JPYamagata University · JP

Funding

Chugai Pharmaceutical Co., Ltd
6 · The paper itself

Abstract

We investigated the efficacy and safety of further bevacizumab therapy in patients with platinum-resistant ovarian cancer whose disease had progressed after bevacizumab plus chemotherapy. In this multicenter, open-label, phase II trial (JGOG3023), patients were randomized 1:1 to a single-agent chemotherapy alone (either pegylated liposomal doxorubicin [40 or 50 mg/m

Indexed as

AgedAntineoplastic AgentsBevacizumabDrug Resistance, NeoplasmFallopian Tube NeoplasmsFemaleHumansMiddle AgedOvarian NeoplasmsPeritoneal NeoplasmsPlatinumStandard of CareSurvival AnalysisTreatment OutcomeAntineoplastic AgentsBevacizumabPlatinumbevacizumabfallopian tube cancerovarian cancerperitoneal cancerplatinum resistance

Identifiers

PMID34716979
PMCPMC8748228
OpenAlexW3211196596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.